Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Delamanid

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 25, 2020

            Details:

            Deltyba has potent bactericidal activity against Mycobacterium tuberculosis and is the first approved compound from the bicyclic nitro-imidazole derivatives for the treatment of pulmonary MDR-TB in adult patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Influenza HA Vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Kitasato Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: $3.5 million

            Deal Type: Agreement March 27, 2020

            Details:

            After a review of sales strategy and discussions, the companies have reached an agreement to terminate the cooperative sales agreement for Influenza HA Vaccine.